Neoadjuvant chemotherapy before CRS/HIPEC for metachronous colorectal peritoneal metastases offers no survival benefit and increases complication risks. Patients receiving neoadjuvant chemotherapy had a complication rate of 25% versus 12.7% for those undergoing upfront surgery. Length of hospital stay increased to 12 days with neoadjuvant treatment compared to 10 days without. Surgeons should weigh these risks […]
Category: Cytoreductive Surgery & Peritoneum
High Variation in Expert Assessment of Peritoneal Malignancy
Surgeons face significant interobserver variation in evaluating peritoneal lesions despite their experience. Consensus on lesion scoring achieved in only 22.5% of cases among 50 expert surgeons (α = 0.174). Agreement on morphologic terms reached in 26.5% of images (α = 0.0902), with “tumor nodule” used 90.4% of the time (p < 0.001). Consensus prediction of […]
Gastric Cancer Peritoneal Metastasis Management Consensus Established
New guidelines for managing gastric cancer peritoneal metastasis (gcpm) offer surgeons a pathway to improve patient outcomes. Experts developed 13 consensus statements on diagnosis and treatment, with 75-100% agreement among a global panel. A broader survey yielded 12 out of 13 consensus among 63 experts, but only 52% agreed on systemic treatment best practices. This […]
PIPAC Treatment Linked to Longer Survival in Unresectable Malignancies
More treatments with pressurized intraperitoneal aerosol chemotherapy (PIPAC) lead to better survival outcomes for patients with unresectable peritoneal surface malignancies (PSMs). Patients receiving 3 or more PIPAC procedures showed significantly improved survival. Disease progression (56%) was the main reason for stopping treatment, signaling the need for ongoing evaluation of therapy effectiveness. Surgeons should consider the […]
Laparoscopic surgery yields similar outcomes for colorectal peritoneal metastases.
Survival rates are comparable: median overall survival is 37.3 months with laparoscopic versus 34.1 months with open surgery. Postoperative complications are similar in both groups, but hospital stays are shorter for laparoscopic patients. Patient selection is crucial; extraperitoneal metastasis significantly impacts survival outcomes. Consider laparoscopic cytoreductive surgery for suitable patients to enhance recovery without compromising […]
New Consensus Guidelines for Peritoneal Mesothelioma Care
A recent consensus on managing peritoneal mesothelioma reaffirms critical treatment strategies. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard for completely resectable cases. Strong agreement on using cisplatin-doxorubicin for HIPEC in routine care and performing a total parietal peritonectomy for all patients. Neoadjuvant chemotherapy recommended for patients with sarcomatoid or biphasic subtypes and […]
Cytoreductive Surgery Best Practices for Peritoneal Malignancies
New guidelines for cytoreductive surgery (CRS) emphasize improved patient outcomes through standardized techniques. 81.5% consensus on 31 of 38 key surgical questions, indicating areas of agreement among leading surgeons. Strong recommendation for specialist pathologists and thorough evaluations of CRS specimens. Standardized practices can enhance surgical precision and patient selection, potentially reducing complications in high-stakes procedures. […]
CRS/HIPEC Improves Survival in Low-Grade Appendiceal Carcinoma
CRS/HIPEC significantly enhances survival for select low-grade appendiceal carcinoma patients with peritoneal and parenchymal metastases. Median overall survival (OS) for low-grade mucinous and non-mucinous patients after CRS/HIPEC was not reached, compared to 50 months for surgery alone and 26 months for systemic chemotherapy (p < 0.01). In multivariable analysis, CRS/HIPEC reduced mortality risk for low-grade […]
Prophylactic CRS and HIPEC Elevate Outcomes in Appendiceal Cancer
Prophylactic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) offers significantly improved survival for patients with perforated appendiceal adenocarcinoma. Five-year overall survival with prophylactic CRS + HIPEC was 96.9% vs. 51.9% for conventional carcinologic resection. Five-year disease-free survival was 75.2% with prophylactic treatment compared to 34.3% in the standard group. This approach should be a standard […]
Gastric Cancer Treatment Shift: Prioritizing Patient Outcomes
Gastric cancer with peritoneal metastases is rising, especially in younger patients, highlighting the urgent need for better outcomes. Novel therapies like normothermic intraperitoneal and systemic chemotherapy have shown overall survival benefits. Patient-reported outcomes remain underreported in major trials, with critical insights missed from studies like Dragon-01. Incorporating tailored patient-reported measures into clinical trials is essential […]